Skip to content

The Orthokin trial, a prospective double blind placebo controlled randomized trial to investigate the effectiveness of autologous Interleukin-1 receptor antagonist in the treatment of osteoarthritis (OA).

The Orthokin trial, a prospective double blind placebo controlled randomized trial to investigate the effectiveness of autologous Interleukin-1 receptor antagonist in the treatment of osteoarthritis (OA).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22051
Enrollment
182
Registered
2005-09-12
Start date
2004-01-27
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OA of the knee.

Interventions

Inclusion interview, X-rays of the knee and filling out questionnaires. Vena punction. Six intra-articular injections of the afflicted knee with Orthokin or placebo. Every 3 months visiting treati

Sponsors

Dr. D.B.F. Saris University Medical Center Utrecht Department of Orthopaedics PO box 85500 3508 GA, Utrecht The Netherlands +31 30 2506971
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Typical symptoms for osteoarthritis as judged by the physician; 2. Previous treatment more than 6 months ago; 3. Patient signed informed consent; 4. Patient > 18 years old; 5. Minimal 40 mm VAS pain; 6. Maximal 60 points Knee Society Rating Scale; 7. Maximal 60 points KOOS index.

Exclusion criteria

Exclusion criteria: 1. Participation in concurrent trials; 2. Participation in previous trials within 3 months; 3. Patient know with HIV, Hepatitis, CMV and Syphilis infections; 4. Alcohol and drug abuse; 5. Poor general health condition as judged by the treating physician; 6. Received hyaluronic acid and/or corticosteroid intra-articular injections into the afflicted knee within the last 6 months of baseline; 7. Intake of specific drugs, such as chondroitin sulfate, diacerein, n-glucosamine, piacledine, capsain within 2 weeks of the baseline visit; 8. Any concomitant painful or disabling disease of the spine, the hips or lower limbs that would interfere with evaluation of the afflicted knee; 9. Ipsilateral coxarhrosis and hip prothesis loosening; 10. Any clinically significant or symptomatic vascular or neurological disorder of the lower extremities; 11. All crystalline, inflammatory and infectious arthropathies; 12. Current diagnosis of osteomyelitis. OA grade IV; 13. Known immunodeficiency; 14. Corticosteroid usage; 15. Anti-coagulant usage and coagulopathy; 16. Morbid obesity.

Design outcomes

Primary

MeasureTime frame
Questionnaires.

Secondary

MeasureTime frame
X-rays.

Contacts

Public ContactN.J.H. Raijmakers

University Medical Center Utrecht (UMCU), Department of Orthopaedics, P.O. Box 85500

n.j.h.raijmakers@chir.azu.nl+31 (0)30 2506972

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)